10-Q: Akebia Therapeutics Q1 2026 Results Show Revenue Dip

Akebia Therapeutics reported a decrease in net product revenue for the first quarter of 2026, primarily driven by lower Auryxia sales, partially offset by increased Vafseo revenue.

Summary

• Akebia Therapeutics reported total revenues of $53.5 million for the three months ended March 31, 2026, a decrease from $57.3 million in the same period of 2025.
• Net product revenue declined by 7% to $52.0 million, mainly due to lower Auryxia sales, which were impacted by the loss of exclusivity in March 2025 and the subsequent market entry of a generic version.
• Vafseo revenue increased to $15.8 million from $12.0 million in the prior year's quarter.
• Cost of goods sold increased significantly by 61% to $12.3 million, attributed to higher inventory write-downs.
• Research and development expenses rose by 52% to $14.8 million, driven by increased clinical trial activities for praliciguat and AKB-9090.
• Selling, general, and administrative expenses increased by 18% to $30.4 million, primarily due to higher headcount-related costs.
• The company reported a net loss of $9.1 million for the quarter, compared to a net income of $6.1 million in the first quarter of 2025.
• As of March 31, 2026, Akebia had $162.6 million in cash and cash equivalents.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the decline in revenue, increased operating expenses, and a shift from profit to loss, despite positive Vafseo revenue growth and a solid cash position.

Positives

• Vafseo revenue increased to $15.8 million, up from $12.0 million in the prior year's quarter, indicating market penetration for the drug.
• The company maintains a substantial cash position of $162.6 million as of March 31, 2026, providing a runway for operations.
• The company continues to advance its pipeline with praliciguat and AKB-9090, with clinical trial activities increasing.

Negatives

• Total revenues decreased by 7% to $53.5 million compared to the prior year's quarter.
• Net product revenue declined by 7% to $52.0 million, primarily due to lower Auryxia sales following loss of exclusivity and generic competition.
• Cost of goods sold increased significantly by 61% to $12.3 million, largely due to higher inventory write-downs.
• The company reported a net loss of $9.1 million for the quarter, a reversal from a net income of $6.1 million in the prior year.
• Research and development expenses increased by 52% to $14.8 million, indicating higher investment in pipeline development.
• Selling, general, and administrative expenses increased by 18% to $30.4 million, impacting overall profitability.

Risks

• The company faces significant risks related to its financial position and the need for additional financing, as it has incurred substantial losses since inception and anticipates continued losses.
• The commercial success of Auryxia and Vafseo is critical, and failure to maintain contracts or market acceptance could materially harm results.
• The entry of generic versions of Auryxia is expected to adversely impact future revenue.
• Clinical drug development is lengthy, expensive, and uncertain, with a high risk of failure.
• The company is dependent on third-party manufacturers and distributors, and disruptions in supply could harm the business.
• Failure to adequately protect intellectual property could adversely affect the company's ability to compete.
• The company is subject to complex regulatory schemes requiring significant resources for compliance.
• Disruptions at regulatory agencies like the FDA could hinder the development and approval of product candidates.
• Legislative and regulatory healthcare reform may increase the difficulty and cost of obtaining marketing approval and commercializing products.
• The company's stock price has been and may continue to be volatile.
• The company may require substantial additional financing, and a failure to obtain capital when needed could force delays or termination of product development or commercialization efforts.

Future Outlook

The company believes its existing cash resources and expected future revenues are sufficient to fund its current operating plan for at least two years, including commercializing Vafseo and Auryxia and advancing existing programs. However, significant deterioration in operating performance or failure to achieve Vafseo revenue projections could adversely affect liquidity and the ability to continue as a going concern. The company may seek additional financing through equity or debt transactions, or strategic transactions.

Management Comments

• The company expects Teva's entry into the market, and the entry of any additional generic versions of Auryxia, to adversely impact revenue.
• The company expects its cost of product and other revenue for Vafseo will increase, reflecting the full cost of manufacturing, subsequent to the utilization of its reduced-cost Vafseo inventory.
• The company expects to incur significant R&D expenses in future periods in support of ongoing or planned studies with respect to the development of its product candidates.

Industry Context

StockSavvy.ai notes that Akebia Therapeutics is operating in the highly competitive biopharmaceutical sector, specifically focusing on kidney disease therapeutics. The company's performance is significantly influenced by the lifecycle management of its products, particularly Auryxia facing generic competition and Vafseo's market penetration post-launch. The increasing R&D spend reflects a strategic focus on pipeline development for rare kidney diseases, a segment often characterized by unmet medical needs and potential for premium pricing, but also by high development risks and smaller patient populations.

Comparison to Industry Standards

• The company's R&D expenses as a percentage of revenue (approximately 27.6% for Q1 2026) are within the typical range for mid-stage biopharmaceutical companies investing heavily in pipeline development.
• The significant increase in Cost of Goods Sold (COGS) as a percentage of revenue (approximately 23.7% for Q1 2026) compared to the prior year (approximately 13.3%) is notable and driven by inventory write-downs, which is a concern for operational efficiency.
• The net loss reported ($9.1 million) is a common occurrence for companies in this stage of development, but the shift from a net profit in the prior year's quarter to a loss highlights the impact of increased operating expenses and decreased revenue.

Legal Proceedings

• Opposition proceedings against Akebia's Indian Patent No. 287720 covering vadadustat.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity issuance.
• The decline in revenue and net loss could negatively impact shareholder value.
• Dialysis organizations and other customers are key to product sales, and maintaining contracts is crucial.
• Suppliers and contract manufacturers are critical for product supply, and any disruptions could impact the company's ability to meet demand.

Next Steps

• Continue commercialization of Vafseo in the U.S.
• Advance mid-stage pipeline assets, praliciguat and AKB-097.
• Evaluate AKB-097 for IgA Nephropathy, C3 Glomerulopathy, and Lupus Nephritis in a Phase 2 basket study.
• Initiate Phase 1 study for AKB-9090 for cardiac surgery-related acute kidney injury.
• Continue preclinical development for AKB-10108.
• Explore additional commercial and development opportunities.
• Manage operating expenses and liquidity.

Key Dates

Recommendation

While the company has a solid cash position and positive developments in its Vafseo sales and pipeline, the decline in overall revenue, increased expenses, and the shift to a net loss are concerning. The significant impact of generic competition on Auryxia revenue and the ongoing R&D investments with uncertain outcomes warrant a cautious approach. Investors should monitor Vafseo's market penetration and pipeline progress closely.

Keywords

Akebia Therapeutics, Form 10-Q, Quarterly Report, Vafseo, Auryxia, vadadustat, ferric citrate, CKD, anemia, hyperphosphatemia, financial results, revenue, net loss, R&D expenses, SG&A expenses